Cancer Registry Software Market Research Report By Type (Integrated Software, Standalone Software), Deployment Model (Cloud-Based, On-Premise), Database Type (Commercial, Public), Functionality (Patient Care Management, Product Outcome Evaluation, Cancer Reporting to Meet State, Federal Regulations, Medical Research and Clinical Studies), End User (Hospitals, Medical Practices, Government Organizations, Research Centers, Pharmaceutical, Biotechnology, Medical Device Companies and Others) - Forecast till 2032

Cancer Registry Software Market Overview

The Cancer Registry Software MArket is expected to reach USD 200.4 Million by 2032 at CAGR 10.2% during the forecast period 2023-2032.

A cancer registry is a software database for organizing, collecting, and storing data of cancer patients for evaluation of their treatment outcomes. This software tool helps manage and provide access to information and build cancer registries.

The market’s growth is driven by the demand for proper management of cancer and the rising demand to improve the quality of care and reduce healthcare costs. The higher adoption of EHRs and the increased usage of cancer patient registry data for marketing surveillance are driving the market.

The usage of integrated software in the healthcare industry is mainly due to the changing landscape; the demand for proper streamlined and optimized workflows and decreased physician workloads are enhancing the market’s growth. Other factors such as the emerging government’s focus on population growth, health management, investment in the healthcare sector, and eliminating the higher healthcare costs will boost the market’s growth in the forecast period.

Soon, market growth is anticipated to be boosted by rising cancer prevalence, bettering healthcare quality, cutting healthcare expenses, and recent actions by key players such as product/service announcements and mergers and acquisitions. A rise in the use of cancer registry software is predicted due to many benefits, including effective workflow leadership, automated case registries, and the rising incidence of cancer. Additionally, many government agencies are making efforts, and supporting the development of cancer registries is anticipated to accelerate market expansion. Like this, approvals for products and debuts are other variables for market expansion. Such an abundance of operations demonstrates the high rate of patient adoption of surgery, and as a result, growth is anticipated.

Due to hospitals' huge investments and funding, patients would prefer hospitals if there were more surgeries since they would receive better care there than at other institutions. The main reason driving the market's expansion globally is the rising use of electronic health records (EHR) and additional e-health technologies like ePrescribing, telemedicine, and others. The demand for proper, streamlined, optimized workflows and reduced physician workloads is boosting the market's growth. This is why integrated software is used in the healthcare sector. Population expansion, health management, investments in the healthcare sector, and eliminating the higher healthcare expenses are other aspects that will enhance the market's growth during the projection period. In addition, user-friendly cloud-based patient registration systems have become an effective tool with improved data accessibility and immediate evaluation for end users.

Cancer Registry Software Market Segment

The cancer registry software market has been segmented into type, deployment model, database type, functionality, and end user.

By type, the market has been segmented into integrated software and standalone software.

Based on the deployment model, the market has been segmented into cloud-based models and on-premise models.

On the basis of the database type, the market has been segmented into commercial databases and public databases.

By functionality, the market has been segmented into patient care management, product outcome evaluation, cancer reporting to meet state and federal regulations, medical research & clinical studies.

The market, by end user, has been segmented into hospitals & medical practices, government organizations & research centers, pharmaceutical, biotechnology, and medical device companies, and others.

The cancer registry software market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada.  

The European cancer registry software market has been segmented into Western Europe and Eastern Europe. Western Europe market has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe.   

The cancer registry software market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The market in the Middle East & Africa has been segmented into the Middle East and Africa.

News:

The GO2 Foundation for Lung Cancer announced the enhanced and extended Global Lung Cancer Registry to significantly advance lung cancer research by revealing hidden links between persons with lung cancer worldwide. The Global Lung Cancer Registry, an expansion of the GO2 Foundation's national registry, will securely collect information from lung cancer patients worldwide, giving researchers rich data to discover trends that could result in novel and better treatments for those with lung cancer. The registration will be accessible in Simplified Chinese, English, Spanish, German, and French the following year. Scientific investigation into how each person's disease interacts with or resists treatment has led to the development novel lung cancer medicines. To understand more about gene alterations and improve the quality of life for those undergoing therapy, researchers can examine interactions among cases within the Global Lung Cancer Registry. They can then use this information to develop medications and potential cures.

Regional Market Summary Cancer registry software market Share (%), by Region, 2018 Source: White Papers, Company Presentations, Annual Reports

On a regional basis, the Americas is anticipated to dominate the cancer registry software market owing to the rising prevalence of cancer, innovative product development and increasing investment in research and development for innovation in the region.   According to the National Cancer Institute, there were 1,735,350 new cases of cancer in the US in 2018.

Europe is expected to hold the second largest position in the market owing to the presence of strong academic & research base and availability of funding for research in the European countries.

Asia-Pacific is anticipated to be the fastest growing region in the market owing to the shift of pharmaceutical companies to countries such as India and China, which are low-cost manufacturing regions.

The Middle East & Africa has the least share of the cancer registry software market.  Moreover, the major market share of the region is expected to be held by the Middle East region owing to the growing government initiatives for the healthcare sector.

Cancer Registry Software Market Segmentation

Cancer Registry Software Type Outlook

• Integrated Software


• Standalone Software

Cancer Registry Software Deployment Model Outlook

• Cloud-Based Models


• On-Premise Models

Cancer Registry Software Database Type Outlook

• Commercial Databases


• Public Databases

Cancer Registry Software Functionality Outlook

• Patient Care Management


• Product Outcome Evaluation


• Cancer Reporting to Meet State and Federal Regulations


• Medical Research & Clinical Studies

Cancer Registry Software End User Outlook

• Hospitals & Medical Practices


• Government Organizations & Research Centers


• Pharmaceutical, Biotechnology, and Medical Device Companies


• Others

Cancer Registry Software Region Outlook

• Americas




• North America




• US


• Canada




• Latin America




• Europe




• Western Europe




• Germany


• France


• Italy


• Spain


• UK


• Rest of Western Europe




• Eastern Europe




• Asia-Pacific




• Japan


• China


• India


• Australia


• South Korea


• Rest of Asia-Pacific




• The Middle East & Africa




• Middle East


• Africa

Recent Development

In May 2022

Veeva Systems has declared that Lucid Diagnostics Inc., a commercial-stage, which is a cancer prevention medical diagnostics company with an owned subsidiary of PAVmed Inc., has selected Veeva Vault CDMS for capturing electronic data, coding, and data cleaning in the upcoming research EsoGuard in patients who are undergoing standard for, and management of, esophageal adenocarcinoma.

In May 2022

Taipei Veteran’s General Hospital is a first-class medical center and teaching hospital in Taiwan. TVGH and a major electronics brand joined forces in AI-based medicine for intensive care of early warning systems for shock and an individualized cancer treatment system.

Together, the hospital-private sector collaboration declared their result in the field of AI-based precision medicine. They established a warning system for shock in intensive care patients. In addition, the collaboration has led to the analysis of patients with hepatobiliary cancer, rectal, and gastrointestinal. It is used to predict a patient’s disease duration and treatment outcomes. Intended Audience

• Software companies


• Contract research organizations


• Academic and research institutes


• Government associations